Cellvie Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5M
- Investors
-
7
Cellvie General Information
Description
Developer of mitochondria-based therapeutic technology intended to restore cellular bioenergetics and improve organ function. The company utilizes isolated mitochondria derived from donor cells to repair damaged or energy-depleted cells through infusion, enabling the healthcare providers to address conditions linked to mitochondrial dysfunction.
Contact Information
Website
www.cellvie.bioCorporate Office
- Scotland Street
- Houston, TX 77007
- United States
Corporate Office
- Scotland Street
- Houston, TX 77007
- United States
Cellvie Timeline
Cellvie Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 09-Sep-2025 | $5M | Completed | Pre-Clinical Trials | ||
| 6. Grant | 24-Oct-2024 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series A) | Cancelled | Pre-Clinical Trials | ||||
| 4. Seed Round | 06-Feb-2023 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 25-Jan-2021 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Jun-2020 | $25K | $25K | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Jan-2018 | Completed | Startup |
Cellvie Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cellvie Patents
Cellvie Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023283025-A1 | Composition and method for cryopreservation of mitochondria | Pending | 10-Jun-2022 | ||
| EP-4535996-A1 | Composition and method for cryopreservation of mitochondria | Pending | 10-Jun-2022 | ||
| US-20250361490-A1 | Composition and method for cryopreservation of mitochondria | Pending | 10-Jun-2022 | ||
| WO-2023237789-A1 | Composition and method for cryopreservation of mitochondria | Inactive | 10-Jun-2022 | ||
| AU-2023285014-A1 | Mitochondria as a targeted delivery platform | Pending | 10-Jun-2022 | C12N15/87 |
Cellvie Signals
Cellvie Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Beiersdorf Venture Capital | Corporate Venture Capital | Minority | ||
| Innosuisse | Government | |||
| Beiersdorf | Corporation | Minority | ||
| Taiho Ventures | Corporate Venture Capital | Minority | ||
| Kizoo Technology Capital | Venture Capital | Minority |
Cellvie FAQs
-
When was Cellvie founded?
Cellvie was founded in 2018.
-
Where is Cellvie headquartered?
Cellvie is headquartered in Houston, TX.
-
What is the size of Cellvie?
Cellvie has 10 total employees.
-
What industry is Cellvie in?
Cellvie’s primary industry is Biotechnology.
-
Is Cellvie a private or public company?
Cellvie is a Private company.
-
What is Cellvie’s current revenue?
The current revenue for Cellvie is .
-
How much funding has Cellvie raised over time?
Cellvie has raised $15.5M.
-
Who are Cellvie’s investors?
Beiersdorf Venture Capital, Innosuisse, Beiersdorf, Taiho Ventures, and Kizoo Technology Capital are 5 of 7 investors who have invested in Cellvie.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process